Pengfei Gao

Pengfei Gao


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2024 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
PGPengfei Gao
Pengfei Gao
YLYanjiao Lu
Yanjiao Lu
KTKun Tang
Kun Tang
WWWei Wang
Wei Wang
TWTongsheng Wang
Tongsheng Wang
YMYi min Mao
Yi min Mao
Ficolins were originally identified as proteins that bind to transforming growth factor-β1 (TGF-β1). They are capable of activating the complement system through lectin pathway for immune system protection. Ficolin-2 and 3 have been identified in patients with interstitial lung diseases (ILD) and their function in these diseases is currently being explored. In contrast, the functional role of ficolin-1 in pulmonary fibrosis is still elusive and remains to be elucidated. The expression of ficolin-1 in the plasma of idiopathic pulmonary fibrosis (IPF) and connective tissue disease (CTD)-ILD patients was first determined. As the orthologue of human ficolin-1, ficolin-B knockout and ficolin-B overexpression were used to establish bleomycin (BLM)-induced pulmonary fibrosis mouse model. Co-immunoprecipitation, immunofluorescence and RNA sequencing were utilized to explore and expound on the expression and the functional mechanism of ficolin-1 in pulmonary fibrosis. Compared with healthy controls, plasma ficolin-1 was significantly decreased in patients with IPF and CTD-ILD. In the bleomycin (BLM)-induced mice model, ficolin-B deficiency aggravated lung injury and fibrosis. There was also observed increase in TGF-β1 levels and enhanced downstream signaling. However, the overexpression of ficolin-B showed preventative and therapeutic efficacy against lung fibrosis. Furthermore, coimmunoprecipitation studies revealed the direct interaction between ficolin-1 and TGF-β1 in human plasma, which was further confirmed by the colocalization of ficolin-1 and TGF-β1 in lung tissues. Ficolin-1 inhibits pulmonary fibrosis by directly binding to the key profibrogenic factor TGF-β1, marking it as a potential target for therapy in the treatment of fibrotic lung diseases.

13 May 2018 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
PGPengfei Gao
Pengfei Gao
KTKun Tang
Kun Tang
MWMeijia Wang
Meijia Wang
QYQun Yang
Qun Yang
YXYongjian Xu
Yongjian Xu
JXJungang Xie
Jungang Xie

24 November 2023 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
PGPengfei Gao
Pengfei Gao
KTKun Tang
Kun Tang
YLYanjiao Lu
Yanjiao Lu
MWMeijia Wang
Meijia Wang
WWWei Wang
Wei Wang
YMYimin Mao
Yimin Mao
Background: The activated complement cascade is involved in asthmatic airway inflammation. Ficolins are essential for innate immunity and can activate the complement lectin pathway. Despite this, the significance of ficolins in asthma has yet to be determined. This study aimed to explore the presence of ficolins in individuals with asthma and to determine the relationship between ficolins and clinical characteristics. Methods: For the study, 68 asthmatic patients and 30 healthy control subjects were recruited. Enzyme-linked immunosorbent assay was used to determine plasma ficolin-1, ficolin-2, and ficolin-3 concentrations both before and after inhaled corticosteroid (ICS) therapy. Further, the associations of plasma ficolin-1 level with pulmonary function and asthma control questionnaire (ACQ) score were examined in the asthma patients. Results: Patients with asthma exhibited significantly elevated plasma ficolin-1 levels (median, 493.9 ng/mL; IQR, 330.2–717.8 ng/mL) in comparison to healthy controls (median, 330.6 ng/mL; IQR, 233.8–371.1 ng/mL). After ICS treatment, plasma ficolin-1 (median, 518.1 ng/mL; IQR, 330.2–727.0 ng/mL) in asthmatic patients was significantly reduced (median, 374.7 ng/mL; IQR, 254.8–562.5 ng/mL). Additionally, ficolin-1 expressions in plasma were significantly correlated with pulmonary function parameters and ACQ score in asthmatic patients. Asthma patients with higher plasma ficolin-1 levels demonstrated poorer lung function than those with lower plasma ficolin-1 levels. Conclusions: The results revealed that asthmatic patients had higher plasma ficolin-1 concentrations, which decreased after ICS treatment and were linked to their lung function, implying a potential involvement of ficolin-1 in asthma pathogenesis.

23 January 2024 in Respiratory Research
Verified
Journal Article
Open access
PDF file
YZYan Zhang
Yan Zhang
YZYang Zhang
Yang Zhang
WWWei Wang
Wei Wang
XFXiaoyu Feng
Xiaoyu Feng
JGJiahuan Guo
Jiahuan Guo
PGPengfei Gao
Pengfei Gao
Background: Computed tomography (CT) scan is commonly performed for pleural effusion diagnostis in the clinic. However, there are limited data assessing the accuracy of thoracic CT for the separation of transudative from exudative effusions. The study aimed to determine the diagnostic value of thoracic CT in distinguishing transudates from exudates in patients with pleural effusion. Methods: This is a two-center retrospective analysis of patients with pleural effusion, a total of 209 patients were included from The First Affiliated Hospital of Henan University of Science and Technology as the derivation cohort (Luoyang cohort), and 195 patients from the First Affiliated Hospital of Zhengzhou University as the validation cohort (Zhengzhou cohort). Patients who underwent thoracic CT scan followed by diagnostic thoracentesis were enrolled. The optimal cut-points of CT value in pleural fluid (PF) and PF to blood CT value ratio for predicting a transudative vs. exudative pleural effusions were determined in the derivation cohort and further verified in the validation cohort. Results: In the Derivation (Luoyang) cohort, patients with exudates had significantly higher CT value [13.01 (10.01–16.11) vs. 4.89 (2.31–9.83) HU] and PF to blood CT value ratio [0.37 (0.27–0.53) vs. 0.16 (0.07–0.26)] than those with transudates. With a cut-off value of 10.81 HU, the area under the curve (AUC), sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of CT value were 0.85, 88.89%, 68.90%, 43.96%, and 95.76%, respectively. The optimum cut-value for PF to blood CT value ratio was 0.27 with AUC of 0.86, yielding a sensitivity of 61.11%, specificity of 86.36%, PPV of 78.57%, and NPV of 73.08%. These were further verified in the Validation (Zhengzhou) cohort. Conclusions: CT value and PF to blood CT value ratio showed good differential abilities in predicting transudates from exudates, which may help to avoid unnecessary thoracentesis.

16 September 2013 in Journal of Inorganic Materials
Verified
Journal Article
Closed access
XYXiao-Lei Yu
Xiao-Lei Yu
Jun YangJun Yang
Jun Yang
XFXue-Jiao Feng
Xue-Jiao Feng
PGPengfei Gao
Pengfei Gao
JWJiu-Lin Wang
Jiu-Lin Wang
YNYan-Na Nuli
Yan-Na Nuli
Lotus root-like porous silicon / carbon composite was synthesized via magnesiothermic reduction and chemical vapor deposition (CVD) method, using mesoporous silica SBA-15 as silicon source. X-ray diffraction (XRD), scanning electron microscope (SEM), transmission electron microscope (TEM) and nitrogen adsorption-desorption measurements were used to study the effects of the raw material ratio, mixing-pressing method and reaction temperature on the phase composition and morphology of the lotus root-like porous silicon. The optimal synthesis condition of porous silicon is that the uniformly mixed precursors with the excess amount of 20wt% Mg powder after ball-milling are directly reacted at 750¡æ for 4 h. The electrochemical tests reveal the porous silicon/carbon composite material maintains the reversible capacity of 1633.1 mAh/g at a current density of 0.5 A/g after 70 charge-discharge cycles, and attains 580.1 mAh/g even at 8 A/g

25 August 2025 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
FZFuyun Zhang
Fuyun Zhang
HWHuanhuan Wang
Huanhuan Wang
WWWei Wang
Wei Wang
YZYingwei Zhu
Yingwei Zhu
YMYimin Mao
Yimin Mao
PGPengfei Gao
Pengfei Gao
Induced sputum is a noninvasive, safe, cost-effective, and reproducible method that is particularly advantageous for individuals who do not naturally produce sputum or provide inadequate samples. Its higher quality than spontaneously produced sputum makes it valuable in various respiratory conditions such as chronic obstructive pulmonary disease, asthma, lung cancer, and infectious respiratory diseases. Despite its potential, the clinical use of induced sputum is limited. In conditions like interstitial lung disease, where patients often have a dry cough, induced sputum shows promise, albeit with limited research. This review emphasizes the usefulness of induced sputum in such conditions, aiming for induced sputum to be established as a routine supplementary examination in clinical settings.